1949 related articles for article (PubMed ID: 30961656)
1. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
2. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
3. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
4. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
6. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
7. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
8. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
10. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
11. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
12. Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.
Le Gall C; Cammarata A; de Haas L; Ramos-Tomillero I; Cuenca-Escalona J; Schouren K; Wijfjes Z; Becker AMD; Bödder J; Dölen Y; de Vries IJM; Figdor CG; Flórez-Grau G; Verdoes M
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35428705
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
16. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
17. cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.
Ferris ST; Ohara RA; Ou F; Wu R; Huang X; Kim S; Chen J; Liu TT; Schreiber RD; Murphy TL; Murphy KM
Cancer Immunol Res; 2022 Aug; 10(8):920-931. PubMed ID: 35648641
[TBL] [Abstract][Full Text] [Related]
18. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
19. A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
Gleisner MA; Pereda C; Tittarelli A; Navarrete M; Fuentes C; Ávalos I; Tempio F; Araya JP; Becker MI; González FE; López MN; Salazar-Onfray F
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690772
[TBL] [Abstract][Full Text] [Related]
20. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
